Gene Expression Data From New Analysis Method Supports That a Larger Proportion of Patients will Benefit From Arfolitixorin

GOTHENBURG, Sweden, March 30, 2020 /PRNewswire/ -- Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that new gene expression data based on a validated method from TATAA Biocenter AB, which is significantly more sensitive than the pre-commercial...

from PR Newswire: https://ift.tt/2UNSCtY